Loading...
Market
Market performance of Roche's obesity drug in its first year post-approval
4
Resolution / Starting Odds
Becomes market leader in obesity drugs • 30%
Performs moderately without leading the market • 30%
Underperforms compared to existing treatments • 40%
Market analysis reports and Roche's annual financial reports
Story
Roche's Obesity Drug Shows Positive Phase I Results, Shares Rise 4.7% After 18.8% Weight Loss
May 16, 2024, 09:25 AM
Roche has reported positive Phase I results for its experimental obesity drug, developed by newly acquired Carmot Therapeutics. The trial showed an average weight loss of approximately 18.8%, leading to a 4.7% increase in Roche shares at the market open on Thursday. The company described the results as 'encouraging' amidst growing competition in the obesity drug market. This marks the first clinical readout since Roche acquired Carmot Therapeutics for $2.7 billion.
View original story
Similar markets
Outperforms • 25%
Underperforms • 25%
Matches • 25%
Data Inconclusive • 25%
Yes • 50%
No • 50%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Performs better than average • 33%
Performs on par with average • 34%
Underperforms compared to average • 33%
Significant stock price increase (>15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (<5%) • 25%
Stock price decrease • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase in market share • 33%
No change • 33%
Decrease in market share • 34%
Significant stock price increase (over 15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (0-5%) • 25%
Stock price decrease • 25%
Highly positive outcomes • 25%
Moderately positive outcomes • 25%
Neutral outcomes • 25%
Negative outcomes • 25%
Outperforms all major competitors • 33%
Performs on par with major competitors • 33%
Underperforms against major competitors • 33%